resTORbio to stop RTB101 development for symptomatic respiratory illness
resTORbio has discontinued the development of RTB101, a TORC1 inhibitor, for the prevention of clinically symptomatic respiratory illness (CSRI) after the drug failed to meet the primary endpoint of the PROTECTOR 1 Phase 3 study. The US biopharma company was conducting the PROTECTOR 1 clinical trial for assessing the safety and efficacy of RTB101 for […]